Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Sales (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Return on Sales for 9 consecutive years, with 0.19% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales rose 30.0% to 0.19% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.02%, a 41.0% increase, with the full-year FY2025 number at 0.02%, up 41.0% from a year prior.
  • Return on Sales was 0.19% for Q4 2025 at Akebia Therapeutics, down from 0.01% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.2% in Q2 2022 to a low of 1.59% in Q2 2021.
  • A 5-year average of 0.55% and a median of 0.42% in 2024 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was 277bps in 2021; the steepest drop was -65bps in 2021.
  • Akebia Therapeutics' Return on Sales stood at 1.22% in 2021, then surged by 97bps to 0.04% in 2022, then skyrocketed by 128bps to 0.01% in 2023, then plummeted by -4589bps to 0.49% in 2024, then soared by 60bps to 0.19% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Return on Sales are 0.19% (Q4 2025), 0.01% (Q3 2025), and 0.0% (Q2 2025).